Pfizer Inc.'s roughly $350m investment in a new biosimilars center in China appears aimed at tapping into China's stated policy of adding value and modernizing its biopharma sector, as well as bring on line important new global production capacity.
New $350m Site To Build Pfizer’s China Biosimilar Capacity
While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.